Japan Major Depressive Disorder (MDD) Market Forecast and Opportunities 2020-2030: Increasing Awareness and Decreasing Stigma of Mental Health Disorders
September 16, 2024 06:15 ET
|
Research and Markets
Dublin, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The "Japan Major Depressive Disorder (MDD) Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has been added to ...
Psychedelic Therapeutics Clinical Trials Research Report 2024 Featuring Yale University, Johnson & Johnson, Shire Pharmaceuticals, Pfizer, Lykos, and UCB
September 13, 2024 06:55 ET
|
Research and Markets
Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trials: Psychedelic Therapeutics" report has been added to ResearchAndMarkets.com's offering.This report provides a review of global...
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
September 11, 2024 08:55 ET
|
PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024 09:07 ET
|
PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
August 13, 2024 07:00 ET
|
atai Life Sciences
VLS-01 demonstrated a good safety and tolerability profile and a short psychedelic experience, enabling a total in-clinic treatment of two hours.
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application
August 09, 2024 21:33 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024 18:18 ET
|
PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024 07:00 ET
|
atai Life Sciences
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference in August 2024
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
July 30, 2024 08:55 ET
|
PharmAla Biotech
PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update
Psychedelic Drug (Ketamine, Psilocybin) Research Report 2024: A Global $4.6 Billion Market by 2030 - Strategic Analysis, Trends, Forecasts and Competitive Analysis 2018-2023 & 2024-2030
July 24, 2024 09:50 ET
|
Research and Markets
Dublin, July 24, 2024 (GLOBE NEWSWIRE) -- The "Psychedelic Drug Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...